Andrew’s patent practice is principally in the pharmaceutical and chemical fields. He has extensive experience in securing patent protection for pharmaceuticals and specialises in drafting and prosecuting patent applications covering new chemical entities, salts, polymorphs, formulations (including advanced drug delivery technologies), manufacturing processes, medical uses, and medical devices. Outside of the pharmaceutical field, Andrew’s practice encompasses agrochemicals, polymer chemistry, petroleum additives, catalytic compositions, separation chemistry, adhesive technologies and biosensors.
Andrew acts for a diverse range of clients, including international corporations, universities, start-up companies and associate patent attorney firms based outside of the UK.
He commenced his patent career in private practice before joining the in-house patent department of a major multi-national pharmaceutical company in June 2004. As an in-house attorney, Andrew was responsible for the patent portfolios relating to a number of high priority drug development projects, as well as conducting IP due diligence evaluations to support in-licensing activities. Andrew returned to private practice in November 2008 when he joined the Manchester office of HGF as a Partner.
Andrew draws on both his private practice and in-house experience to provide commercially-focused advice to his clients in relation to all patent matters, including patent portfolio management, enforcing patent rights, challenging third party patent rights, providing infringement and validity opinions, and conducting due diligence evaluations to support licensing and acquisition deals. Andrew also has considerable experience in representing clients in opposition and appeal proceedings at the European Patent Office.
The development and evaluation of microparticulate formulations for DNA immunisation
Postgraduate Certificate in Intellectual Property Law
Andrew is listed in the IAM Strategy 300 as a leading IP strategist
Andrew is listed in the IAM Patent 1000 as a leading IP attorney in his field.
Andrew is listed as a MIP Star.
Andrew mentors and contributes to the professional training of Trainee Patent Attorneys within HGF, as well as mentoring and training of IP and technology transfer professionals in other organisations.
Oral proceedings by videoconference can be enforced by the EPO during the pandemic On 16 July 2021 the EPO’s Enlarged Board of Appeal (EBoA) decided on referral G 1/21 regarding …Read article
HGF in Europe and Shiga in Japan are holding a joint webinar on 29th July 2021. Fitter, faster, stronger – patenting sports and fitness technology in Europe and Japan Sporting …Event details
The IAM Patent 1000 – the world’s leading patent professionals 2021 guide has now been published. HGF has 18 European attorneys listed. IAM Patent 1000 is a unique guide that …Read article
WIPR Patents Live is holding a complimentary session on July 20, at 5pm BST/12pm ET, where HGF Partner & Patent Attorney Kieran Killough will present on ‘Protecting medical devices in …Event details
G1/21 hearing continues on 2nd July 2021. Follow this page for updates from HGF Partner Douglas Drysdale and Patent Director Ellie Purnell, who will be reporting all the key moments …Read article
HGF is hosting a ‘Patents for the offshore sector’ webinar on 13th July, 2021. The webinar will be presented by HGF Patent Director Richard Gover. It will include an introduction …Event details
The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’. Such a refusal can …Read article
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.